FDA Biosimilars Approvals

Monday September 20, 2021

FDA Biosimilars Approvals

BiosimilarApproved Launched
AVASTIN (BEVACIZUMAB)
Mvasi (bevacizumab-awwb)Sept-17Jul-19
Zirabev (bevacizumab-bvzr)Jun-19Dec-19
ENBREL (ETANERCEPT)
Erelzi (etanercept-szzs)Aug-16
Eticovo (etanercept-ykro)Apr-19
EPOGEN/PROCRIT (EPOETIN ALFA)
Retacrit (epoetinalfa-epbx)May-18Nov-18
HERCEPTIN (TRASTUZUMAB)
Ogivri (trastuzumab-dkst)Dec-17Dec-19
Herzuma (trastuzumab-pkrb)Dec-18Mar-20
Ontruzant (trastuzumab-dttb)Jan-19April-20
Trazimera (trastuzumab-qyyp) Mar-19Feb-20
Kanjinti (trastuzumab-anns)Jun-19Jul-19
HUMIRA (ADALIMUMAB)
Amjevita (adalimumab-atto)Sept-16
Cyltezo (adalimumab-adbm)Sept-16
Hyrimoz (adalimumab-adaz)Oct-18
Hadlima (adalimumab-bwwd)Jul-19
Abrilada (adalimumab-afzb)Nov-19
Hulio (adalimumab-fkjp)Jul-20
Yusimry (adalimumab-aqvh)Dec-21
LANTUS (INSULIN GLARGINE)
Rezvoglar (insuline glargine-aglr)Dec-21
Semglee (insulin glargine-yfgn)Jul-21Nov-21
LUCENTIS (RANIBIZUMAB)
Byooviz (ranibizumab-nuna)Sept-21
NEULASTA (PEGFILGRASTIM)
Fulphila (pegfilgrastim-jmdb)Jun-18Jun-18
Nyvepria (pegfilgrastim-apgf)Jun-20Dec-20
Udenyca (pegfilgrastim-cbqv)Nov-18Jan-19
Ziextenzo (pegfilgrastim-bmez)Nov-19Dec-19
NEUPOGEN (FILGRASTIM)
Zarxio (filgrastim-sndz)Mar-15Sep-15
Nivestym (filgrastim-aafi) Jul-18Oct-18
REMICADE (INFLIXIMAB)
Inflectra (infliximab-dyyb)Apr-16Nov-16
Renflexis (infliximab-abda)Apr-17Jul-17
Ixifi (infliximab-qbtx)Dec-17
Avsola (infliximab-axxq)Dec-19Jul-20
RITUXAN (RITUXIMAB)
Truxima (rituximab-abbs)Nov-18Nov-19
Ruxience (rituximab-pvvr)Jul-19Feb-20
Riabni (rituximab-arrx)Dec-20Jan-21
Total: 33 approved, 21 launched*As of December 2021
Source: FDA

Stay Informed

Subscribe for Updates

Receive our monthly Biosimilars Bulletin and other important updates on biosimilars in the U.S.

  • This field is for validation purposes and should be left unchanged.

Get Involved

The Council is involved in a number of events that focus on advancing biosimilars in the United States. Click on one below to learn more:

February 14-16, 2022 | Orlando, Florida

Access! brings together policymakers, influential speakers and industry leaders to chart the future of generics and biosimilars. This year, we're pleased to be meeting in person for the first time since 2019! Sign up before December 31, 2021 to receive $500 off your full-pass registration.

Recent Tweets

Proposals included in #BuildBackBetter undermine the progress and promise of future #biosimilar savings, particularly for employers and patients in commercial health insurance markets.

Learn more in our latest blog post: https://biosimilarscouncil.org/resource/proposed-bbb-negotiation-framework-discourages-biosimilar-competition-imposes-higher-costs-on-commercially-insured-patients-and-their-employers/

Load More...